Design of Escherichia Coli-expressed Stalk Domain Immunogens of H1N1 Hemagglutinin That Protect Mice from Lethal Challenge

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2012 Sep 28

PMID 23015722

Citations 46

Authors

Gayathri Bommakanti

Xianghan Lu

Michael P Citron

Tariq Ahmad Najar

Gwendolyn J Heidecker

Jan Ter Meulen

Raghavan Varadarajan

Xiaoping Liang

Affiliations

Soon will be listed here.

Abstract

The hemagglutinin protein (HA) on the surface of influenza virus is essential for viral entry into the host cells. The HA1 subunit of HA is also the primary target for neutralizing antibodies. The HA2 subunit is less exposed on the virion surface and more conserved than HA1. We have previously designed an HA2-based immunogen derived from the sequence of the H3N2 A/HK/68 virus. In the present study, we report the design of an HA2-based immunogen from the H1N1 subtype (PR/8/34). This immunogen (H1HA0HA6) and its circular permutant (H1HA6) were well folded and provided complete protection against homologous viral challenge. Antisera of immunized mice showed cross-reactivity with HA proteins of different strains and subtypes. Although no neutralization was observable in a conventional neutralization assay, sera of immunized guinea pigs competed with a broadly neutralizing antibody, CR6261, for binding to recombinant Viet/04 HA protein, suggesting that CR6261-like antibodies were elicited by the immunogens. Stem domain immunogens from a seasonal H1N1 strain (A/NC/20/99) and a recent pandemic strain (A/Cal/07/09) provided cross-protection against A/PR/8/34 viral challenge. HA2-containing stem domain immunogens therefore have the potential to provide subtype-specific protection.

Citing Articles

Induction of enhanced stem-directed neutralizing antibodies by HA2-16 ferritin nanoparticles with H3 influenza virus boost.

Wang Q, Nie J, Liu Z, Chang Y, Wei Y, Yao X Nanoscale Adv. 2025; .

PMID: 39974341 PMC: 11833233. DOI: 10.1039/d4na00964a.

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.

Casazza J, Hofstetter A, Costner P, Holman L, Hendel C, Widge A NPJ Vaccines. 2024; 9(1):171.

PMID: 39289377 PMC: 11408684. DOI: 10.1038/s41541-024-00959-0.

Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses.

Thulasi Raman S, Zetner A, Hashem A, Patel D, Wu J, Gravel C Emerg Microbes Infect. 2023; 12(1):2192821.

PMID: 36927227 PMC: 10171128. DOI: 10.1080/22221751.2023.2192821.

Comparative Immunogenicity of Bacterially Expressed Soluble Trimers and Nanoparticle Displayed Influenza Hemagglutinin Stem Immunogens.

Kar U, Khaleeq S, Garg P, Bhat M, Reddy P, Vignesh V Front Immunol. 2022; 13:890622.

PMID: 35720346 PMC: 9204493. DOI: 10.3389/fimmu.2022.890622.

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.

Carascal M, Pavon R, Rivera W Front Immunol. 2022; 13:878943.

PMID: 35663997 PMC: 9162156. DOI: 10.3389/fimmu.2022.878943.

References

Chen J, Wharton S, Weissenhorn W, Calder L, Hughson F, Skehel J . A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation. Proc Natl Acad Sci U S A. 1995; 92(26):12205-9. PMC: 40325. DOI: 10.1073/pnas.92.26.12205. View

Throsby M, van den Brink E, Jongeneelen M, Poon L, Alard P, Cornelissen L . Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One. 2008; 3(12):e3942. PMC: 2596486. DOI: 10.1371/journal.pone.0003942. View

Sali A, Blundell T . Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993; 234(3):779-815. DOI: 10.1006/jmbi.1993.1626. View

Stropkovska A, Mucha V, Fislova T, Gocnik M, Kostolansky F, Vareckova E . Broadly cross-reactive monoclonal antibodies against HA2 glycopeptide of Influenza A virus hemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin. Acta Virol. 2009; 53(1):15-20. View

Stevens J, Corper A, Basler C, Taubenberger J, Palese P, Wilson I . Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science. 2004; 303(5665):1866-70. DOI: 10.1126/science.1093373. View

Xu R, Ekiert D, Krause J, Hai R, Crowe Jr J, Wilson I . Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010; 328(5976):357-60. PMC: 2897825. DOI: 10.1126/science.1186430. View

Corti D, Voss J, Gamblin S, Codoni G, Macagno A, Jarrossay D . A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333(6044):850-6. DOI: 10.1126/science.1205669. View

Bullough P, Hughson F, Skehel J, Wiley D . Structure of influenza haemagglutinin at the pH of membrane fusion. Nature. 1994; 371(6492):37-43. DOI: 10.1038/371037a0. View

Matrosovich M, Matrosovich T, Garten W, Klenk H . New low-viscosity overlay medium for viral plaque assays. Virol J. 2006; 3:63. PMC: 1564390. DOI: 10.1186/1743-422X-3-63. View

10.

Kawaoka Y, Yamnikova S, Chambers T, Lvov D, Webster R . Molecular characterization of a new hemagglutinin, subtype H14, of influenza A virus. Virology. 1990; 179(2):759-67. DOI: 10.1016/0042-6822(90)90143-f. View

11.

Smirnov Y, Lipatov A, Gitelman A, Claas E, Osterhaus A . Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol. 2000; 145(8):1733-41. DOI: 10.1007/s007050070088. View

12.

Lee B, Richards F . The interpretation of protein structures: estimation of static accessibility. J Mol Biol. 1971; 55(3):379-400. DOI: 10.1016/0022-2836(71)90324-x. View

13.

Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, Tatusova T . The influenza virus resource at the National Center for Biotechnology Information. J Virol. 2007; 82(2):596-601. PMC: 2224563. DOI: 10.1128/JVI.02005-07. View

14.

GERHARD W . The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol. 2001; 260:171-90. DOI: 10.1007/978-3-662-05783-4_9. View

15.

Wilson I, Skehel J, Wiley D . Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature. 1981; 289(5796):366-73. DOI: 10.1038/289366a0. View

16.

Fouchier R, Munster V, Wallensten A, Bestebroer T, Herfst S, Smith D . Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol. 2005; 79(5):2814-22. PMC: 548452. DOI: 10.1128/JVI.79.5.2814-2822.2005. View

17.

Ekiert D, Bhabha G, Elsliger M, Friesen R, Jongeneelen M, Throsby M . Antibody recognition of a highly conserved influenza virus epitope. Science. 2009; 324(5924):246-51. PMC: 2758658. DOI: 10.1126/science.1171491. View

18.

Chen J, Lee K, Steinhauer D, Stevens D, Skehel J, Wiley D . Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell. 1998; 95(3):409-17. DOI: 10.1016/s0092-8674(00)81771-7. View

19.

Godley L, Pfeifer J, Steinhauer D, Ely B, Shaw G, Kaufmann R . Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity. Cell. 1992; 68(4):635-45. DOI: 10.1016/0092-8674(92)90140-8. View

20.

Correia B, Ban Y, Friend D, Ellingson K, Xu H, Boni E . Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. J Mol Biol. 2010; 405(1):284-97. DOI: 10.1016/j.jmb.2010.09.061. View